The EMA gave a positive opinion for the drug TRYNGOLZA, developed by Ionis Pharmaceuticals, marking a step toward European Commission approval.
2 reports, 2 independent
Updated Jul 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The EMA gave a positive opinion for the drug TRYNGOLZA, developed by Ionis Pharmaceuticals, marking a step toward European Commission approval.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
EMA
Japanese vocalist of the group DUSTCELL
Nothing else this week.
-
European Commission
executive branch of the European Union
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyIonis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Io
- Business WireTRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS) – Recommendation based on Phase 3 Balance results, which showed a significant reduction o